Non-invasive Optical Angiography in Age-related Macular Degeneration

Sponsor
Medical University of Vienna (Other)
Overall Status
Recruiting
CT.gov ID
NCT02521142
Collaborator
(none)
72
1
85
0.8

Study Details

Study Description

Brief Summary

Age-related macular degeneration (AMD) is the leading cause of severe and irreversible visual loss and classified blindness in the elderly throughout Europe and the US. Among these patients, about 6%-8% are afflicted with the advanced stages of AMD, which are responsible for the most severe visual loss. There is now convincing evidence that vascular endothelial growth factor (VEGF) is a major trigger for the formation of pathological choroidal vessels, responsible for the development of the neovascular form of AMD. Today, the gold standard for vascular imaging of the retina and diagnosis of CNV is angiography using fluorescein (FLA) or indocyanine green (ICG), which involves injection of the dye into a vein of the arm. In the recent years tremendous enhancements in the field of optical coherence tomography have been achieved. These developments made it possible to visualize the retinal vasculature in a full depth manner without the application of an intravenous marker. The proposed study tests the hypothesis that visualisation of CNV lesion size with non-invasive OCT angiography is not inferior to FLA/ICG angiography in treatment naïve and previously treated AMD patients.

Condition or Disease Intervention/Treatment Phase
  • Other: Non-invasive OCT based optical angiography
  • Other: Oxymap T1
  • Other: OCT
  • Other: FLA/ICG angiography

Study Design

Study Type:
Observational
Anticipated Enrollment :
72 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Study Start Date :
Nov 1, 2015
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
AMD: treatment-naive

Other: Non-invasive OCT based optical angiography
This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.

Other: Oxymap T1
The Oxymap system T1 is installed on a conventional fundus camera (Topcon TRC-50DX), which is operated as for color photography. The Oxymap T1 simultaneously acquires two images of the same area of the fundus at two different wavelengths of light. One of the two wavelengths is sensitive to oxygen saturation, i.e. the light absorbance changes with the oxygen saturation, while the other is insensitive to oxygen saturation and is used to calibrate the light intensity. The two spectral images are automatically processed by the Oxymap Analyzer software. Oxymap Analyzer detects blood vessels and estimates the light absorbance (optical density) at each point along the vessels at each wavelength. The ratio of the optical densities (optical density ratio or ODR) has been shown to be linearly related to hemoglobin oxygen saturation.

Other: OCT
non-invasive imaging of retinal and choroidal structures.

Other: FLA/ICG angiography
Fluorescein Angiography and Indocianine Angiography

AMD: active neovascular AMD

Other: Non-invasive OCT based optical angiography
This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.

Other: Oxymap T1
The Oxymap system T1 is installed on a conventional fundus camera (Topcon TRC-50DX), which is operated as for color photography. The Oxymap T1 simultaneously acquires two images of the same area of the fundus at two different wavelengths of light. One of the two wavelengths is sensitive to oxygen saturation, i.e. the light absorbance changes with the oxygen saturation, while the other is insensitive to oxygen saturation and is used to calibrate the light intensity. The two spectral images are automatically processed by the Oxymap Analyzer software. Oxymap Analyzer detects blood vessels and estimates the light absorbance (optical density) at each point along the vessels at each wavelength. The ratio of the optical densities (optical density ratio or ODR) has been shown to be linearly related to hemoglobin oxygen saturation.

Other: OCT
non-invasive imaging of retinal and choroidal structures.

Other: FLA/ICG angiography
Fluorescein Angiography and Indocianine Angiography

Outcome Measures

Primary Outcome Measures

  1. Differences in visualization of lesion size between non-invasive OCT based optical angiography and FLA/ICG angiography in treatment-naïve and treated patients with CNV due to AMD. [Participants will be followed for the duration of outpatient clinic visit, an expected average of 1 days]

Secondary Outcome Measures

  1. choroidal thickness as assessed with OCT [participants will be followed for the duration of outpatient clinic visit, an expected average of 1 days]

  2. peripapillarly bloodflow as assessed with Doppler OCT [participants will be followed for the duration of outpatient clinic visit, an expected average of 1 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with active CNV due to AMD as assessed by FLA/ICG angiography within 1 week prior to study inclusion

Exclusion criteria

Any of the following will exclude a patient from the study:
  • Previous application of intravitreal drugs except anti-VEGF injections

  • Active intraocular inflammation

  • Presence of an intraocular disease except AMD and cataract

Contacts and Locations

Locations

Site City State Country Postal Code
1 Medical University of Vienna Vienna Austria 1090

Sponsors and Collaborators

  • Medical University of Vienna

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Stefan Sacu, Prof. Dr., Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT02521142
Other Study ID Numbers:
  • NOAA
First Posted:
Aug 13, 2015
Last Update Posted:
Aug 24, 2022
Last Verified:
Aug 1, 2022
Keywords provided by Stefan Sacu, Prof. Dr., Medical University of Vienna
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 24, 2022